Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiscoverIE Regulatory News (DSCV)

Share Price Information for DiscoverIE (DSCV)

Share Price is delayed by 15 minutes
Get Live Data
678.00    -7.00 (-1.02%)
Bid:
665.00
Ask:
678.00
Spread: 13.00 (1.955%)
Market Cap: £658.48m
DSCV Live PriceLast checked at - London Stock Exchange

Intraday DiscoverIE Share Chart

Interim Management Statement

3 Feb 2010 07:00

RNS Number : 5762G
Acal PLC
03 February 2010
 



 

FOR RELEASE

7.00 AM

03 February 2010

 

 

ACAL plc

("Acal" or "the Group")

 

SECOND INTERIM MANAGEMENT STATEMENT

PERIOD COMMENCING 1 OCTOBER 2009

 DIRECTORATE CHANGE

 

Acal plc, a specialist provider of technology products and services across Europe and South Africa, is today issuing its second Interim Management Statement for the year ending 31 March 2010, which covers the period commencing 1 October 2009 to date and includes the quarter ended 31 December 2009.

 

The Board is pleased to report that since September 2009, trading has improved with the Group now operating profitably. The Group's balance sheet remains robust with a net cash position.

 

Electronics

 

The backlog of orders has increased at a better rate than expected, being 16% higher than the low point of April 2009, and 3% higher year on year (on a consistent basis, unadjusted for currency exchange rate movements). This is starting to translate into improved sales, which in January were around 8% higher than the previous quarter's monthly average. Orders received in the months of December and January continued at the improved level and with a positive book to bill ratio. We expect the improving sales rate to continue throughout the second half.

 

BFi Optilas ("BFi") is seeing a similar improvement. 

Supply Chain and Medical

 

As indicated in the interim results, the Supply Chain division will disengage from a major customer contract at the end of the financial year. As previously stated, losses on this contract have already been eliminated. Underlying Supply Chain sales remain stable although margins are coming under pressure.

 

Trading in the Medical division also remains stable, with sales having increased year on year. As indicated in our interim statement, spending within our UK customers in the NHS has increased in the second half of the year, although we remain cautious for the remainder of the year, as speculation of further spending cut backs continues.

 

The following material events or transactions impacted the Group during the period covered by this interim management statement.

 

Acquisition of BFi

 

On 18 December, the Group completed the acquisition of BFi for a consideration of €10 million and the issue of 2 million Ordinary Shares. The acquisition has doubled the Group's electronic sales which now account for around 70% of Group sales.

 

BFi has already exceeded our expectations in the initial period of ownership, and the process of integrating its operations with the rest of the division is progressing well.

 

Purchase and Leaseback of offices and warehouse in Eindhoven

On 31 December 2009, the Group completed the purchase, sale and leaseback of its offices and warehouse in Eindhoven. This generated a cash inflow of €0.6 million with the profit on sale being amortised over the life of the revised lease agreement.

 

Directorate Change

 

The Group also announces today that Malcolm Cooper, Group Finance Director, has resigned for personal reasons with immediate effect. Until a permanent replacement is found, Paul Neville, Group Commercial Director, will be acting Group Finance Director.

  

Nick Jefferies, Chief Executive Officer commented:

 

"The return to profitability has been achieved by taking decisive actions to reduce operating expenses and increase gross margins. Improving sales trends are now also starting to take effect. We continue to manage the business tightly, and are cautiously optimistic of a sustained improvement in market conditions.

 

We are very pleased to welcome BFi Optilas to the Acal group and are focussedon delivering the significant synergies as we build Europe's leading specialist Electronics and Photonics distributor.

 

I would like to thank Malcolm Cooper for his valuable contribution to Acal over the last ten years, and wish him well for the future."

 

 

For further information:-

 

Nicholas Jefferies ~ Chief Executive

Paul Neville ~ Group Commercial Director

 

Chris Lane / James Verstringhe

Cubitt Consulting

 

01483 544500

01483 544500

 

020 7367 5100

 

 

Notes to the Interim Management Statement

 

(a) This Interim Management Statement has been prepared solely to provide additional information to the shareholders of Acal plc, as a body, in order to meet the requirements of the UK Listing Authority's Disclosure and Transparency Rules.

 

Notes to Editors:

The Acal Group is a leading technology-based specialist distributor in Europe providing sales, marketing and other services through three Divisions: Electronics, Supply Chain and Medical. The Electronics Division distributes electronic products to industrial manufacturing and design companies. The Supply Chain Division supplies new and refurbished IT, EPOS and ATM spare parts to service providers while the Medical Division supplies advanced medical equipment to public and private healthcare providers. Acal has operating companies in the UK, Netherlands, Belgium, Germany, France, Italy, South Africa, Spain and the Nordic region.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRGDDUXGBGGD
Date   Source Headline
11th Jun 202610:00 amRNSDirector LTIP & DSBP Awards
3rd Jun 20267:00 amRNSPreliminary results
20th May 20267:00 amRNSNotice of Full Year Results
19th May 20267:00 amRNSAcquisition of 3Gmetalworx
7th May 20261:29 pmRNSNotification of Major Holdings
17th Apr 20267:00 amRNSQ4 and full year trading update
10th Apr 20269:16 amRNSNotification of Major Holdings
27th Feb 20264:42 pmRNSNotification of Major Holdings
12th Feb 20265:18 pmRNSDirector/PDMR Shareholding
2nd Feb 20267:00 amRNSQ3 Trading Update
29th Jan 20268:58 amRNSDirector/PDMR Shareholding
16th Dec 20254:00 pmRNSNotification of Major Holdings
16th Dec 20259:31 amRNSIssue of Equity & Total Voting Rights
11th Dec 20254:02 pmRNSDirector/PDMR Shareholding
4th Dec 20257:00 amRNSAcquisition of Trival
3rd Dec 20252:55 pmRNSNotification of Major Holdings
2nd Dec 20257:00 amRNSInterim Results
19th Nov 20257:15 amRNSDirector Declaration
18th Nov 20259:16 amRNSNotice of Half Year Results
28th Oct 20257:00 amRNSAppointment of Joint Corporate Broker
16th Oct 20253:41 pmRNSNotification of Major Holdings
14th Oct 20257:00 amRNSFirst Half Trading Update
15th Sep 20252:14 pmRNSNotification of Major Holdings
4th Sep 20252:58 pmRNSNotification of Major Holdings
14th Aug 20251:27 pmRNSDirector/PDMR Shareholding
13th Aug 20258:32 amRNSDirector / PDMR Shareholding
4th Aug 20253:44 pmRNSNotification of Major Holdings
24th Jul 20252:37 pmRNSResults of Annual General Meeting
24th Jul 20257:00 amRNSTrading Update
19th Jun 202511:34 amRNSAnnual Report & Notice of AGM
18th Jun 20258:12 amRNSNotification of Major Holdings
16th Jun 20254:30 pmRNSNotification of Major Holdings
12th Jun 202510:20 amRNSDirector LTIP & DSBP Awards
4th Jun 20257:00 amRNSPreliminary results
14th May 20254:13 pmRNSNotification of Major Holdings
14th May 20252:13 pmRNSNotice of Full Year Results
16th Apr 20254:48 pmRNSNotification of Major Holdings
16th Apr 20257:00 amRNSTrading Update
9th Apr 20258:38 amRNSNotification of Major Holdings
26th Mar 20253:08 pmRNSNotification of Major Holdings
12th Mar 20258:39 amRNSDirector/PDMR Shareholdings
5th Mar 20258:05 amRNSDirector Declaration
3rd Mar 20252:20 pmRNSDirector/PDMR Shareholding
26th Feb 20254:56 pmRNSNotification of Major Holdings
18th Feb 20252:52 pmRNSNotification of Major Holdings
17th Feb 20252:37 pmRNSNotification of Major Holdings
14th Feb 20258:28 amRNSDirector / PDMR Shareholding
5th Feb 20251:08 pmRNSNotification of Major Holdings
30th Jan 20257:00 amRNSQ3 Trading Update
29th Jan 20259:40 amRNSDirector / PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.